Orakl Oncology raises $34M to predict cancer drug results with AI

Paris-based Orakl Oncology has raised a $34M Series A co-led by Norrsken VC and Singular. It grows copies of patients’ tumours in the lab, tests drugs on them and uses AI to predict trial results. It will expand into lung and gastric cancer. Paris-based Orakl Oncology has raised a $34M Series A to predict how […] This story continues at The Next Web